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Abstract
Background: Heterosexual men in South Africa are a large key population to exposure to HIV, yet preferences for
HIV pre-exposure prophylaxis (PrEP) among this population have not, to date, been investigated in the literature.
This paper aims to explore HIV prevention preferences among heterosexual men in urban South Africa, as well as to
examine the demand and characteristics of men who favour long-acting injectable (LAI) PrEP over condoms and
oral PrEP.
Methods: Data were collected among 178 self-reported HIV-negative heterosexual men, who were given example
products and information before being asked which they preferred. Multivariate logistic regression was used to
analyse which characteristics were associated with product choice.
Results: 48% (n = 85) of participants preferred LAI PrEP, while 33% (n = 58) and 20% (n = 35) chose oral PrEP and
condoms respectively. Having children (marginal effect = 0.22; 95% CI [0.01, 0.44]) or having higher risk attitude
scores (marginal effect = 0.03; 95% CI [0.01, 0.06]) was significantly associated with a choice of LAI PrEP, while those
who had unprotected anal intercourse (marginal effect = − 0.42; 95% CI [− 0.57, − 0.27]) and those who were
concerned with protection against other sexually transmitted infections over HIV (marginal effect = − 0.42; 95% CI
[− 0.60, − 0.24]) appeared less likely to prefer LAI PrEP.
Conclusions: The results suggested a relatively high demand and theoretical acceptability for LAI PrEP among
heterosexual men in urban South Africa, but there appeared to be fewer distinct predictors for the willingness to
use LAI PrEP compared to studies conducted among gay and bisexual men and women. Nevertheless, the findings
contribute to the mapping of the demand and determinants of heterosexual men’s preferences for novel
antiretroviral-based prevention in sub-Saharan Africa, and the data could aid in the differentiated design of
future HIV prevention strategies using LAI PrEP in conjunction with other methods.
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Background
South Africa has the highest number of people living
with HIV, which was 7.1 million in 2016 [1]. The high
prevalence is partly attributable to the decrease in AIDS
mortality and the increase in life expectancy [2] due to a
relatively high HIV testing rate [3] and access to anti-
retroviral treatment (ART), which increased from 19% in
2010 to 56% in 2016 [1]. Despite efforts to improve HIV
testing and treatment coverage, in 2016 there were an
estimated 260,000 incident HIV cases among adults
(aged 15 and over) in South Africa, an annual incidence
of 1% [1]. The high rate of new infections possibly
results from multiple factors – biological, socio-behav-
ioural and socio-economic [4]. According to the South
African National HIV Survey [5], the main route of
transmission is through heterosexual sex, which suggests
that alongside the needs of focusing on key populations
such as female sex workers and men who have sex with
men, the heterosexual population should also be a focal
point for effective HIV prevention methods.
There are various HIV prevention products currently
being used or developed. Condoms have been a long-
standing and efficacious method to prevent HIV trans-
mission and other sexually transmitted infections (STIs)
[6], yet consistent condom usage is low in the general
population – only 31.9% of the general population aged
over 15 reported using condoms every time or almost
every time with their last sexual partner in the South Af-
rican National HIV Survey in 2012 [5].
Oral pre-exposure prophylaxis (PrEP) antiretroviral
(ARV) agents have been proven efficacious in clinical tri-
als at preventing HIV acquisition – efficacy ranged from
44 to 75% reduction in HIV acquisition in heterosexual
men and women, men who have sex with men and
people who inject drugs [7]. The regimen most com-
monly used is daily oral emtricitabine plus tenofovir
(FTC/TDF) with regular HIV tests and blood tests to
monitor for adverse effects [8]. Both oral and topical
PrEP products have been more effective in male popula-
tions than female [9, 10], partly explained by adherence,
and partly by pharmacokinetic data indicating higher
colorectal drug concentrations than in the female lower
genital tract [11, 12]. As of May 2018, oral PrEP was
provided to female sex workers, men who have sex with
men, and young people at university and community
testing sites in South Africa [13, 14]. Uptake rates for fe-
male sex workers and men who have sex with men, as of
the end of 2017, were 12 and 47%, respectively. Uptake
rate for young people was not yet available [15].
Altogether, there were an estimated 16,000 oral PrEP
users in South Africa [16].
Long-acting injectable (LAI) PrEP has the potential to
be efficacious, and should only require an injection every
two to three months [17], which may mitigate the
adherence issues of oral PrEP [18, 19]. The phase II
safety trials for long-acting cabotegravir (CAB LA) and
long-acting rilpivirine (RPV LA) have shown both to be
safe and tolerable [20, 21]. The results of CAB LA phase
III efficacy trials (HPTN 083 and 084) focusing on the
populations of men who have sex with men, transgender
women, and women at high risk of acquiring HIV infec-
tion are expected to follow in 2022 [22, 23]. With the
addition of this potential new ARV-based prevention
method, it expands the “PrEP method mix” for a wider
user choice and is expected to increase the acceptability
and uptake of HIV prevention measures [24].
For HIV prevention resources to be deployed as effect-
ively as possible, it is essential to identify who among
potential users might be interested in using different
products. Predominant attention has been paid to key
population groups for HIV transmission, including but
not restricted to men who have sex with men, people
who inject drugs, male and female sex workers and ado-
lescent girls and young women [25–27]. Despite 75% of
new infections in Eastern and Southern Africa being
among heterosexual men and women [28] and broad
roll-out of interventions including voluntary medical
male circumcision, there has been little focus on how
ARV-based prevention could enhance HIV prevention
programmes among heterosexual men.
To make a new treatment or prevention measure ac-
cessible, users’ adoption is one of the essential facets. To
facilitate the adoption by potential users, it entails an
understanding of their needs and preferences for the
new technology early in the development phase [29], as
is commonly done in pre-marketing research of other
consumer products [30]. Given that men in sub-Saharan
Africa were shown to be less likely to engage in the HIV
testing and ART treatment cascade compared with
women [31, 32], it is critical to understand the percep-
tion of men towards a novel ARV-based prevention op-
tion during its development, so as to ensure the product
meets their needs and they will thus use.
There is a rich literature on the willingness to use oral
PrEP in both heterosexual men and men who have sex
with men in low- and middle-income countries (LMIC)
[25, 33–35]; on the other hand, studies investigating
men’s willingness to use LAI PrEP have predominantly
focused on men who have sex with men in high-income
settings. In a study by Meyers et al. [36], 80% of young
men who have sex with men in New York City
expressed interest in using LAI-PrEP, and Parsons et al.
[37] found 46% of gay and bisexual men preferred LAI
PrEP compared to oral PrEP. The commonly mentioned
reasons for preferring LAI PrEP were convenience and
longer protection duration [38]. However, there is yet no
study exploring the preferences of heterosexual men for
LAI PrEP in LMIC settings.
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With a need to understand an important user group’s
demand and perception towards a novel HIV prevention
measure early in the development phase and to fill the
gap in the literature, we used a multivariate logistic re-
gression model to analyse the characteristics of hetero-
sexual men preferring LAI PrEP in South Africa. To the
best of our knowledge, this is the first study exploring
the demand and preference towards LAI PrEP among
sub-Saharan heterosexual men. This paper contributes
to the literature by differentiating heterosexual men who
favour LAI PrEP from others preferring oral PrEP and
condoms, as well as presenting data which could inform
strategies for the future roll-out and the design of more
focused HIV prevention schemes for heterosexual men
in sub-Saharan Africa.
Methods
Data
Secondary data analysis was conducted on survey data
from a study on preferences for new HIV-prevention
technologies in urban South Africa in 2015. A detailed
protocol of the study design, sample selection and sur-
vey methods is presented elsewhere [39, 40]. In brief,
data were collected through a population-based house-
hold survey among 202 adult men. The township of
Vosloorus in Ekurhuleni Metropolitan Municipality,
near Johannesburg, was selected for the surveys, given
the broad range of demographic, socio-economic, and
cultural characteristics within the residential compos-
ition [41]. Ethical approval for the survey was obtained
from both London School of Hygiene and Tropical
Medicine (Ref no. 8451–2) and University of Witwaters-
rand Human Research Ethics Committee (Ref no.
M140614), and informed consent was obtained from all
participants.
Of the 202 men sampled, 178 men self-reported as
HIV-negative and heterosexual. There were three
choices of HIV prevention products in the survey which
the male participants ranked from most to least pre-
ferred. The three options were LAI PrEP, oral PrEP, and
condoms. Participants were asked to rank products after
being given information on each (see Additional file 1:
Appendix 1), an opportunity to hold example products,
and the chance to ask fieldworkers any questions they
had.
Determinants for demanding LAI PrEP
There is limited literature probing the willingness of het-
erosexual men to use LAI PrEP, and we therefore
reviewed studies assessing determinants of willingness to
use LAI or oral PrEP in any population group. The core
literature we followed included a multinational study by
Eisingerich et al. [25] and studies by Meyers et al. [36]
and Parsons et al. [37], with determinants falling into
two categories: socio-demographic factors and risk pro-
file. From a pilot study exploring attributes on HIV
products valued by potential users [39, 41], five key attri-
butes were identified. These attributes were also in-
cluded in this study to examine if they were factors
influencing the willingness to use LAI PrEP in hetero-
sexual men. Based on the literature, we predicted a
priori direction of influence of each variable on the
probability of choosing LAI PrEP. The full list of vari-
ables and the predicted direction of influence can be
found in Table 1.
Socio-demographic factors
The literature suggested that younger participants [25,
37], higher educated [36–38] and with fewer children
[25] were more likely to choose LAI PrEP. Therefore, we
predicted ‘age’ and ‘have children’ to have a negative in-
fluence on the probability for participants to choose LAI
PrEP, whereas ‘finished high school education’ has a
positive impact. Income level was not found to be a de-
terminant affecting the willingness to use LAI PrEP in
the literature [36, 37]. In our study, we defined a
monthly income exceeding ZAR 5000 (USD$ 380) as the
higher-income group, which accounted for the upper
28% of income level in this study population.
Risk profile
According to the Health Belief Model [42], individuals’
perception of their own likelihood of susceptibility to an
illness plays a part in influencing their readiness to take
actions in health-related behaviour. Thus, those who be-
lieve they are more susceptible to contracting HIV might
be more likely to take preventive measures, which sup-
ports the findings in previous literature [25, 36, 37]. Pre-
viously tested for HIV [25], frequent condom use [25],
greater number of sexual partners [36] and engaging in
unprotected anal intercourse (UAI) [37] were identified
as positive predictors for people who are more willing to
use LAI PrEP from the limited existing literature, and
we expected to see the same direction of impact of these
variables on the willingness to uptake LAI PrEP in our
study. Being married or in a steady relationship might
also serve as a proxy for the risk profile of heterosexual
men. However, literature from South Africa showed that
the relationship between HIV and marital status is com-
plex [5, 43, 44], and sexual behaviour might act as an
intervening variable between them [43]. Additionally, we
tested our regression model with and without the rela-
tionship status, and it did not change the results. There-
fore, with the inclusion of variables representing risky
sexual behaviour, we did not include relationship status
as a determinant.
We also asked the participants to assess their own risk
attitudes by choosing a number on a scale ranging from
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1 to 10, whereby 1 was the most risk-averse and 10 was
the most risk-loving. Following the Health Belief Model,
the more risk-loving the participants were, the more
likely they would use preventive products. However, we
were uncertain about which product the participants
would choose.
Product attributes
In the survey, participants were asked to rank five key
pre-defined attributes in the order of importance when
considering an HIV prevention product: how much it
protects one from HIV (‘effectiveness’); whether it can
prevent pregnancy (‘contraception’); how often one has
to use it (‘use frequency’); whether it protects people
from sexually transmitted infections (‘STI prevention’);
and what side effects it might have (‘side effects’). Ques-
tions asked in the survey can be found in (Additional file
1: Appendix 2).
Eighty-three percent of the participants in the study by
Meyers et al. [36] expressed their concern about the ef-
fectiveness of LAI PrEP. Marra & Hankins [26] also
demonstrated that the effectiveness of oral PrEP was one
of the important factors in a survey for the perception
and willingness to use oral PrEP among men who have
sex with men in the Netherlands. Given the effectiveness
of HIV prevention products tends to be a top concern
for users, we did not anticipate people who chose LAI
PrEP to perceive product effectiveness differently from
Table 1 Predicted direction of influence, descriptive statistics of independent variables and results of bivariate analysis
Predicted influence
on the preference
for LAI PrEPa
Full sample
(N = 178)
Preference for HIV prevention products χ2 or coefficient of
univariate logistic
regression, P-value
LAI PrEP (N = 85) Oral PrEP or
condoms (N = 93)
N (%) or
(median, range)
N (%) or
(median, range)
N (%) or
(median, range)
Socio-demographic factors
Age (median, range) – 27 (18–45) 28 (18–45) 27 (18–45) 0.000b, 0.983
Education 0.008, 0.928
Lower than high school – 144 (80.9) 69 (81.2) 75 (80.4)
Finished high school + 34 (19.1) 16 (18.8) 18 (19.6)
Household income > R5000 +/− 49 (27.5) 25 (29.4) 24 (25.8) 0.289, 0.591
Have children – 91 (51.1) 47 (55.3) 44 (47.3) 1.132, 0.287
Median No. of children (range) 1 (0–7) 1 (0–7) 0 (0–4) 0.040b, 0.158
Risk Profile
Self-reported HIV status 1.943, 0.163
Tested, negative + 136 (76.4) 61 (71.7) 75 (80.6)
Not-tested – 42 (23.6) 24 (28.3) 18 (19.4)
More than 1 sexual partner in the last year + 79 (44.4) 40 (47.1) 39 (41.9) 0.472, 0.492
Median No. of sexual partners in the last
year (range)
1 (0–50) 1 (0–50) 1 (0–25) 0.002b, 0.849
Condom usage 0.086, 0.769
Always + 90 (50.6) 42 (49.4) 48 (51.6)
Inconsistent – 88 (49.4) 43 (50.6) 45 (48.4)
Ever had UAI + 10 (6) 1 (1.2) 9 (9.7) 6.053, 0.014
Median score for risk attitude (scale
1 = risk-averse; scale 10 = risk-loving; range)
+/− 7 (1–10) 7 (1–10) 5 (1–10) 0.028b, 0.016
Product Attributes
Effectiveness +/− 148 (83.1) 70 (82.4) 78 (83.9) 0.073, 0.787
Contraception – 10 (5.6) 6 (7.1) 4 (4.3) 0.637, 0.425
Use frequency + 6 (3.4) 4 (4.7) 2 (2.2) 0.890, 0.345
STIs prevention – 12 (6.7) 4 (4.7) 8 (8.6) 1.072, 0.300
Side effects – 7 (4) 2 (2.4) 5 (5.4) 1.075, 0.300
UAI Unprotected anal intercourse, STIs Sexually transmitted infections
a. “+” denotes positive influence; “-” denotes negative influence
b. Used univariate logistic regression
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those who chose other methods. Previous clinical trials
have shown that low adherence compromises the effi-
cacy of oral PrEP, and having to take oral PrEP daily
may confer the difficulty that reduces adherence [45].
Participants in a US study also expressed convenience
and longer protection duration being the reasons for
choosing LAI PrEP [38]. Therefore, we expected people
concerned about ‘use frequency’ would be more willing
to use LAI PrEP. Several studies probing the willingness
to use oral PrEP revealed concerns over potential ad-
verse effects [26, 46]; hence, we anticipated that men in
this study would have the same concern regarding side
effects when considering a newer product, LAI PrEP.
Lastly, as LAI PrEP is not able to prevent pregnancy and
STIs, we predicted ‘contraception’ and ‘STI prevention’
to have a negative influence on the likelihood of choos-
ing LAI PrEP.
Statistical methods
A dichotomous outcome variable was created – with 1
for LAI PrEP being the respondents’ top preferred prod-
uct and 0 if a condom or oral PrEP were preferred. We
first performed a bivariate analysis using Chi-square test
to test independent associations between outcomes and
the predictors (socio-demographic factors, risk profiles
and product attributes); for the associations between
outcomes and predictors which are continuous variables
(age and risk attitude scores), we used univariate logistic
regression. We then conducted a multivariate analysis by
applying logistic regression to analyse determinants of
ranking LAI PrEP over the other two products with the
same set of predictors. An alpha level of 0.05 was used.
We also tested variance inflation factors (VIF) to exam-
ine multicollinearity among the variables. The analysis
was conducted in Stata/SE 13.1.
Survey weighting was applied to the multivariate re-
gression. The participants were divided into two groups
according to the standard cut-off age of young adults
[47]: under 25 years old and aged 25 or above. The pro-
portion of these two age groups was compared with the
proportion of the total South African male population.
Weights were given to the two age groups in our survey
sample to match the proportion in the general popula-
tion with the aim that our results can be generalised to
other provinces in South Africa.
Results
Descriptive statistics and bivariate analysis
The descriptive statistics are presented in Table 1.
Among the three HIV prevention methods, 48% (n = 85)
of participants chose LAI PrEP with 33% (n = 58) and
20% (n = 35) choosing oral PrEP and condoms, respect-
ively. Even though participants were told LAI PrEP was
not available yet, it was the most popular HIV preven-
tion methods in this survey.
The overall median age of the study population was
27 years old (range = 18–45, interquartile range = 23–35).
Twenty-four percent (n = 42) of the participants in this
study had never received an HIV test. Forty-four percent
(n = 79) of men in this study reported having more than
one sexual partner in the past 12 months, and the me-
dian number of sexual partners was one. Forty-nine per-
cent (n = 88) of the participants had unprotected sex
intermittently, and 6 % (n = 10) of the study population
experienced UAI. The median score for the risk attitude
scale was 7, and 56% (n = 100) of the participants con-
sidered themselves to be risk-loving, where they rated
themselves 6 out of 10 or above on the scale. As for the
five product attributes, 83% (n = 148) of men regarded
“efficacy” of the products as the most important attri-
bute when they considered which product to choose,
whereas each of the rest of four attributes was ranked
most important by fewer than 10% of participants
respectively.
The bivariate analysis did not reveal independent asso-
ciations between each predictor and the preference for
LAI PrEP – the only exceptions being the experience of
having UAI (χ2 = 6.05, P = 0.01) and having a higher
risk-attitude score (coefficient = 0.03, P = 0.02). In an
additional bivariate analysis between groups (LAI PrEP
vs. oral PrEP and LAI PrEP vs. condoms), the determi-
nants “had UAI” and “with a higher risk-attitude score”
persisted in showing significant differences between men
in favour of LAI PrEP and those preferring condoms.
The consideration of each product attribute remained
insignificant. (See Additional file 1: Table S1).
Multivariate analysis
The results are presented as marginal effects in Table 2.
VIFs for all variables were below 10, indicating multicol-
linearity is not an issue in this model.
Socio-demographic factors
Men who have children were associated with a higher
likelihood of choosing LAI PrEP relative to childless
men, where the likelihood increased by 22% (marginal
effect = 0.22; 95% CI [0.01, 0.44]). Other variables in this
category did not reach statistical significance.
Risk profile
Somewhat surprisingly, men who have ever had UAI were
associated with a decreased probability of 42% (marginal
effect = − 0.42; 95% CI [− 0.57, − 0.27]) of choosing LAI
PrEP compared to those who never had a UAI. Regarding
the self-rated risk attitude score, the increase of one point
on the risk scale was associated with a 3% (marginal ef-
fect = 0.03; 95% CI [0.01, 0.06]) increased likelihood of
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choosing LAI PrEP, which suggests that a risk attitude
score of 10 predicts roughly 30% higher probability of
choosing LAI PrEP compared to the most risk-averse
(with score 1). No association was found between the
choice of LAI PrEP with having been previously tested for
HIV, frequent condom use or having multiple sexual
partners.
Product attributes
Respondents who valued the provision of STI prevention
the most were associated with 42% (marginal effect = −
0.42; 95% CI [− 0.60, − 0.24]) less likely to choose LAI
PrEP. The preference for the rest of the product attri-
butes did not show significant association on the choice
of LAI PrEP.
Discussion
The aim of this study was to investigate the HIV preven-
tion preferences among heterosexual men, as well as to
examine the demand and a priori determinants of men
who favour LAI PrEP in particular over other products,
in order to contribute to the notably limited literature
exploring the acceptability of ARV-based HIV preven-
tion products among heterosexual men in LMICs.
Almost half of the participants in this study indicated
a preference for LAI PrEP over oral PrEP or condoms,
with the effectiveness of the HIV prevention method be-
ing the most important product attribute. Bivariate ana-
lysis showed the independent associations between the
preference for LAI PrEP and experience of unprotected
anal intercourse as well as risk-loving attitude. The re-
sults of multivariate logistic regression highlighted that
men who have children and who scored higher risk atti-
tude scale were more likely to choose LAI PrEP as their
preferred HIV prevention method. On the contrary, men
in this study were more likely to choose the other two
HIV prevention products, oral PrEP or male condoms, if
they valued whether the products prevented other STIs,
or if they ever had unprotected anal intercourse.
Men who are more risk-loving (with higher scores in
the risk attitude scale) were shown to be associated with a
higher likelihood to demand LAI PrEP. To our knowledge,
no literature explored the relationship between risk atti-
tude and the preference of HIV prevention products.
However, studies have shown some risky sexual behav-
iours, e.g., multiple sexual partners [36] and unprotected
anal sex with casual partners [37], are associated with
preference for LAI PrEP. This might indirectly indicate
the association between risk-loving attitude and the
Table 2 Marginal effects of multivariate logistic regression: probability of choosing LAI PrEP as preferred product
Coefficient 95% CI P-value
Socio-demographic factors
Age − 0.004 − 0.018, 0.010 0.581
Education
Lower than high school (as reference) – – –
Finished high school 0.007 −0.248, 0.263 0.954
Household income > R5000 0.024 −0.182, 0.231 0.818
Have children 0.224 0.012, 0.435 0.038
Risk Profile
Tested HIV before 0.106 −0.094, 0.306 0.300
Multiple sexual partners in the last year 0.008 −0.167, 0.183 0.930
Condom usage
Always 0.073 −0.109, 0.255 0.433
Inconsistent (as reference) – – –
Ever had UAI −0.420 −0.574, − 0.265 0.000
Score for risk attitude (scale 1 = risk-averse; scale 10 = risk-loving) 0.034 0.006, 0.063 0.017
Product Attributes
Effectiveness −0.293 −0.679, 0.093 0.137
Contraception −0.081 −0.632, 0.470 0.773
Use frequency −0.016 −0.506, 0.473 0.949
STIs prevention −0.417 −0.596, − 0.237 0.000
Side effects −0.316 − 0.651, 0.019 0.065
UAI Unprotected anal intercourse, STIs Sexually transmitted infections
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preference for LAI PrEP, but it still warrants further study.
It is also plausible that those who perceived the ability to
prevent other STIs as the most important attribute for an
HIV prevention product may not take up LAI PrEP, given
LAI PrEP does not have this attribute.
Two statistically significant determinants, ‘having chil-
dren’ and ‘ever had UAI,’ influenced the likelihood of
choosing LAI PrEP in the opposite direction as we pre-
dicted. Having children was identified as a determinant
that would increase the likelihood of choosing LAI PrEP
in our study, whereas the opposite was found by Eisin-
gerich et al. [25] However, the populations in the survey
by Eisingerich et al. who were likely to have children
were young women, female sex workers, and serodiscor-
dant couples [25]. Little literature was found to discuss
the influence of the number of children on the willing-
ness of using either LAI PrEP or oral PrEP in any of
these groups. Therefore, it is unclear that the inconsist-
ent findings in our study and the literature were due to
the differences between males and females, which would
require future study to explore.
Parsons et al. [37] revealed that gay and bisexual men
who had UAI in the previous three months were associ-
ated with the preference for LAI PrEP. In contrast to
heterosexual men, a higher proportion of gay and bisex-
ual men would engage in unprotected receptive anal
intercourse (URAI), which was found to be associated
with higher uptake of oral PrEP in a cohort study on gay
and bisexual men [48]. Literature suggested that the per-
partner HIV transmission risk is double for URAI com-
pared to unprotected insertive anal intercourse (UIAI),
at 40 and 22% respectively [49]. Following the Health
Belief Model, given the higher risk of URAI, gay and bi-
sexual men might have a higher demand for more effect-
ive HIV prevention methods than heterosexual men
(mostly engaged in UIAI), which provides a potential ex-
planation for why we did not find UAI as a positive pre-
dictor for choosing LAI PrEP in our study.
Among studies exploring the predictors for the prefer-
ence for LAI PrEP, Meyers et al. [36] discovered that
men who have sex with men in New York City, who had
a history of STIs and multiple sexual partners in the pre-
vious three months, had a higher willingness to use LAI
PrEP, whereas people with higher socioeconomic status
and a college degree had a lower willingness. Two US
studies in men who have sex with men also revealed that
age and higher education attainment were positively as-
sociated with the preference for LAI PrEP, and the aver-
age age for people who favour LAI PrEP was 40 and 24
years old, respectively [37, 50]. A multinational study on
female sex workers, men who have sex with men, sero-
discordant couples, people who inject drugs, and young
women also found that people who had been tested for
HIV and those with frequent condom use might prefer
oral PrEP [25]. In our study, age, education, income, pre-
viously tested for HIV, having multiple sexual partners,
and always using a condom did not demonstrate differ-
ences in the preference for LAI PrEP compared to other
HIV prevention products. It is not clear whether the dis-
crepancy is due to different populations (men who have
sex with men, females and heterosexual men) or differ-
ent geographical regions and contexts (the US and South
Africa), which would also be important to assess in fu-
ture research.
Study limitations
There are some limitations in this study. Firstly, all vari-
ables came from self-reported data which are inherently
subject to response bias, especially when the participants
were asked the questions about their risk profile by the
interviewer. For example, although the stigma against
HIV has improved in the past decade [5], the disclosure
of HIV status is still of concern in South African society
[5, 51]. Therefore, the self-reported HIV-positive status
might be underreported.
Another limitation is that the costs of the three prod-
ucts were not considered in this study. As LAI PrEP is
under development, it is unclear if an effective LAI will
be developed, or whether it would be sufficiently cost-ef-
fective to be made available in LMIC contexts. Some
studies have demonstrated that participants are more
willing to take up PrEP if it is offered for free at the
point of access [46, 52, 53]. Therefore, the financial sus-
tainability of LAI programmes will need to be consid-
ered against the need to maximise uptake.
Finally, indicating product preference in a survey may
not mean that men are able to initiate and sustain effect-
ive use of LAI PrEP, or any preventative product. Future
research is needed on how individual, social, and struc-
tural factors may influence product uptake and use.
Conclusions
LAI PrEP has relatively high theoretical acceptability
among heterosexual men in urban South Africa, where
the effectiveness of products is found to be highly crit-
ical to the attractiveness of an HIV prevention product.
However, there appeared to be less distinct determinants
to predict the willingness of men to take up LAI PrEP
compared to the studies conducted among gay and bi-
sexual men and women – the only positive predictors
found in this study were having children and being more
risk-loving. Heterosexual men are an under-researched
but critical population in the HIV response in countries
with a generalised HIV epidemic; more research is
needed to explore how preferences in this group differ
from other key population groups. Nonetheless, the find-
ings from this study suggest there is demand for LAI
PrEP in urban heterosexual men in South Africa, and
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these data can aid in the differentiated design of future
HIV prevention strategies using LAI PrEP in conjunc-
tion with other methods.
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Additional file 1: Appendix 1. Product information provided prior to
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results of bivariate analysis by preferences (LAI PrEP, oral PrEP and
condoms). (DOCX 30 kb)
Abbreviations
AIDS: acquired immunodeficiency syndrome; ART: antiretroviral therapy;
ARV: antiretroviral; CI: confidence interval; HIV: human immunodeficiency
virus; LAI PrEP: long-acting injectable pre-exposure prophylaxis; LMIC: low-
and middle-income country; PrEP: pre-exposure prophylaxis; STI: sexually
transmitted infection; UAI: unprotected anal intercourse; UIAI: unprotected
insertive anal intercourse; URAI: unprotected receptive anal intercourse
Acknowledgements
We thank all participants for their time and effort completing the survey. We
acknowledge the fieldworkers of Progressus Research and Development,
ably supported by the management team of Motlalepule Tsepe, Cornelius
Monkwe, Lindokuhle Xulu and Reathe Rain-Taljaard. We acknowledge the
valuable input of Sinead Delany-Moretlwe, alongside Maria Sibanyoni, Nyar-
adzo Mutanha and the great teams of peer educators at Wits RHI and the
Center for Positive Care, Ekurhuleni.
Authors’ contributions
CYC, MQ, RE, MC, PV and FTP conceptualised and designed the study; MQ,
RE, MC and FTP conducted the fieldwork and collected the data; CYC
analysed the data and drafted the manuscript with MQ and FTP; RE and PV
critically revised the manuscript. All authors have read and approved the
manuscript.
Funding
Fieldwork was supported by the Bill and Melinda Gates Foundation and
analysis by an Economic and Social Research Council 1 + 3 studentship.
Support for the analysis of this project is made possible by the generous
support of the American people through the United States Agency for
International Development (USAID) under the terms of the HealthTech V
Cooperative Agreement #AID-OAA-A-11-00051. We also acknowledge the
financial support by Deutsche Forschungsgemeinschaft within the funding
programme Open Access Publishing, by the Baden-Württemberg Ministry of
Science, Research and the Arts, by Ruprecht-Karls-Universität Heidelberg, and
by the RCUK open access funding at the LSHTM.No funder had a role in the
study design, data collection, analysis and interpretation or writing of this art-
icle. The contents are the responsibility of LSHTM and PATH and do not ne-
cessarily reflect the views of USAID or the US Government.
Availability of data and materials
Data would be made available by the corresponding author upon
reasonable request.
Ethics approval and consent to participate
Ethical approval for the survey study was obtained from both London
School of Hygiene and Tropical Medicine (8451–2) and University of
Witwatersrand Human Research Ethics Committee (M140614). All procedures
performed in studies involving human participants were in accordance with
the ethical standards of the institutional research committees and with the
1964 Helsinki declaration and its later amendments or comparable ethical
standards. Written informed consent was obtained from all survey
participants.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Faculty of Public Health and Policy, London School of Hygiene and Tropical
Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK. 2Medical Faculty
Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim,
Germany. 3Division of Health Economics, German Cancer Research Center
(DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. 4Wits RHI,
University of the Witwatersrand, 22 Esselen Street, Hillbrow, Johannesburg
2001, South Africa. 5School of Social and Community Medicine, University of
Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK.
Received: 24 July 2018 Accepted: 3 July 2019
References
1. UNAIDS. AIDSinfo. 2018. http://aidsinfo.unaids.org/. Accessed 22 May 2018.
2. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser
O, et al. Life expectancies of South African adults starting antiretroviral
treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:
e1001418.
3. Johnson LF, Rehle TM, Jooste S, Bekker L-G. Rates of HIV testing and
diagnosis in South Africa: successes and challenges. Aids. 2015;29:1401–9.
https://doi.org/10.1097/QAD.0000000000000721.
4. Zuma K, Shisana O, Rehle TM, Simbayi LC, Jooste S, Zungu N, et al. New
insights into HIV epidemic in South Africa: key findings from the national
HIV prevalence, incidence and behaviour survey, 2012. African J AIDS Res.
2016;15:67–75.
5. Shisana O, Rehle T, LC S, Zuma K, Jooste S, Zungu N, et al. South African
national HIV prevalence, incidence and behaviour survey, 2012. Cape Town:
HSRC press; 2014.
6. Weller S, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV
transmission. Cochrane Libr. 2002. https://doi.org/10.1002/14651858.
CD003255.
7. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et
al. Effectiveness and safety of oral HIV preexposure prophylaxis for all
populations. Aids. 2016;30:1973–83.
8. Bekker L-G, Rebe K, Venter F, Maartens G, Moorhouse M, Conradie F, et
al. Southern African guidelines on the safe use of pre-exposure
prophylaxis in persons at risk of acquiring HIV-1 infection. South Afr J
HIV Med. 2016;17:1–11.
9. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA,
Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in
injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a
randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;
381:2083–90.
10. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al.
Preexposure chemoprophylaxis for HIV prevention in men who have sex
with men. N Engl J Med. 2010;363:2587–99.
11. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM,
et al. Antiretroviral Preexposure prophylaxis for heterosexual HIV
transmission in Botswana. N Engl J Med. 2012;367:423–34.
12. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-
exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD):
effectiveness results from the pilot phase of a pragmatic open-label
randomised trial. Lancet. 2016;387:53–60.
13. South African National Department of Health. Guidelines for expanding
combination prevention and treatment options for sex workers: oral pre-
exposure prophylaxis (PrEP) and test and treat (T&T). Final Draft; 2016.
https://doi.org/10.5424/fs/2012212-02289.
14. Cairns G. PrEP spreads across Africa – slowly. 2018. http://www.aidsmap.
com/PrEP-spreads-across-Africa-slowly/page/3318441/#item3318444.
Accessed 3 Feb 2019.
15. Dunbar MS, Kripke K, Haberer J, Castor D, Dalal S, Mukoma W, et al.
Understanding and measuring uptake and coverage of oral pre-exposure
prophylaxis delivery among adolescent girls and young women in sub-
Saharan Africa. Sex Health. 2018;15:513–21.
16. AVAC. South Africa – PrEPWatch. 2018. https://www.prepwatch.org/country/
south-africa/. Accessed 16 Feb 2019.
Cheng et al. BMC Public Health          (2019) 19:996 Page 8 of 9
17. Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of long-acting
injectable agents for HIV prevention. Curr Opin HIV AIDS. 2016;11:122–8.
18. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al.
Preexposure prophylaxis for HIV infection among African women. N Engl J
Med. 2012;367:411–22.
19. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al.
Tenofovir-based preexposure prophylaxis for HIV infection among African
women. N Engl J Med. 2015;372:509–18.
20. Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety
and tolerability of long-acting cabotegravir injections in HIV-uninfected men
(ECLAIR): a multicentre, double-blind, randomised, placebo-controlled,
phase 2a trial. Lancet HIV. 2017;4:e331–40.
21. Bekker LG, Li SS, Tolley B, Marzinke MA, Mgodi N, Justman JE, et al. HPTN
076: TMC278 la safe, tolerable, and acceptable for HIV preexposure
prophylaxis. In: Topics in antiviral medicine; 2017. p. 172s–3s.
22. HPTN 083. Safety and efficacy study of injectable cabotegravir compared to
daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), for pre-
exposure prophylaxis in HIV-Uninfected cisgender men and transgender
women who have sex with men. https://clinicaltrials.gov/ct2/show/NCT0272
0094. Accessed 8 Feb 2019.
23. HPTN 084. Evaluating the safety and efficacy of long-acting injectable
cabotegravir compared to daily oral TDF/FTC for pre-exposure prophylaxis
in HIV-uninfected women. https://clinicaltrials.gov/ct2/show/NCT03164564.
Accessed 8 Feb 2019.
24. Meyers K, Golub SA. Planning ahead for implementation of long-acting HIV
prevention. Curr Opin HIV AIDS. 2015;10:290–5.
25. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK.
Attitudes and acceptance of Oral and parenteral HIV Preexposure
prophylaxis among potential user Groups: a multinational study. PLoS One.
2012;7:e28238.
26. Marra E, Hankins CA. Perceptions among Dutch men who have sex with men
and their willingness to use rectal microbicides and oral pre-exposure prophylaxis
to reduce HIV risk – a preliminary study. AIDS Care. 2015;27:1493–500.
27. Rosenthal E, Piroth L, Cua E, Joulié A, Ravaux I, Chauveau M, et al.
Preexposure prophylaxis ( PrEP ) of HIV infection in France : a nationwide
cross-sectional study ( PREVIC study ). AIDS Care. 2014;26:176–85.
28. UNAIDS. Global AIDS Update 2016. Geneva: Switzerland; 2016. http://www.
unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.
Accessed 17 Jan 2018
29. Frost LJ, Reich MR. Creating access to health technologies in poor countries.
Health Aff. 2009;28:962–73.
30. Piot P. Innovation and technology for global public health. Glob Public
Health. 2012;7:S46–53.
31. Fleming PJ, Colvin C, Peacock D, Dworkin SL. What role can gender-
transformative programming for men play in increasing men’s HIV testing
and engagement in HIV care and treatment in South Africa? Cult Health
Sex. 2016;18:1251–64.
32. Underwood C, Hendrickson Z, Van Lith LM, Lengwe Kunda JE, Mallalieu EC.
Role of community-level factors across the treatment cascade: a critical
review. J Acquir Immune Defic Syndr. 2014;66(Suppl.3):311–8.
33. Heffron R, Ngure K, Mugo N, Celum C, Kurth A, Curran K, et al. Willingness
of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1
prevention strategies. J Acquir Immune Defic Syndr. 2012;61:116–9.
34. Mijiti P, Yahepu D, Zhong X, Sun Y, Zhao T, Zhao Z, et al. Awareness of and
willingness to use Oral pre-exposure prophylaxis for HIV prevention among
HIV-Serodiscordant heterosexual couples: a cross-sectional survey in
Xinjiang, China. PLoS One. 2013;8:e67392.
35. Yi S, Tuot S, Mwai GW, Ngin C, Chhim K, Pal K, et al. Awareness and
willingness to use HIV pre-exposure prophylaxis among men who have sex
with men in low- and middle-income countries: a systematic review and
meta-analysis. J Int AIDS Soc. 2017;20:21580.
36. Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High
interest in a long-acting injectable formulation of pre-exposure prophylaxis
for HIV in young men who have sex with men in NYC: a P18 cohort
substudy. PLoS One. 2014;9:1–16.
37. Parsons JT, Rendina HJ, Whitfield THF, Grov C. Familiarity with and
preferences for Oral and long-acting injectable HIV pre-exposure
prophylaxis (PrEP) in a National Sample of gay and bisexual men in the U.S.
AIDS Behav. 2016;20:1390–9.
38. John SA, Whitfield THF, Rendina HJ, Parsons JT, Grov C. Will gay and
bisexual men taking Oral pre-exposure prophylaxis (PrEP) switch to long-
acting injectable PrEP should it become available? AIDS Behav. 2018;22:
1184–9.
39. Quaife M, Eakle R, Cabrera M, Vickerman P, Tsepe M, Cianci F, et al.
Preferences for ARV-based HIV prevention methods among men and
women, adolescent girls and female sex workers in Gauteng Province,
South Africa: a protocol for a discrete choice experiment. BMJ Open. 2016;6.
https://doi.org/10.1136/bmjopen-2015-010682.
40. Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M,
Mvundura M, et al. Divergent preferences for HIV prevention: a discrete
choice experiment for multipurpose HIV prevention products in South
Africa. Med Decis Mak. 2018;38:120–33.
41. Terris-Prestholt F, Hanson K, MacPhail C, Vickerman P, Rees H, Watts C. How much
demand for new HIV prevention technologies can we really expect? Results from
a discrete choice experiment in South Africa. PLoS One. 2013;8:e83193.
42. Becker M, Maiman L. Sociobehavioral determinants of compliance with
health and medical care recommendations. Med Care. 1975;13:10–24.
43. Shisana O, Zungu-Dirwayi N, Toefy Y, Simbayi LC, Malik S, Zuma K. Marital
status and risk of HIV infection in South Africa. South African Med J. 2004;94:
537–43.
44. Johnson L, Dorrington R, Bradshaw D, Pillay-Van Wyk V, Rehle T. Sexual
behaviour patterns in South Africa and their association with the spread of
HIV: insights from a mathematical model. Demogr Res. 2009;21:289–340.
45. Kashuba ADM, Patterson KB, Dumond JB, Cohen MS. Pre-exposure
prophylaxis for HIV prevention: how to predict success. Lancet. 2012;379:
2409–11.
46. Kubicek K, Arauz-Cuadra C, Kipke MD. Attitudes and perceptions of
biomedical HIV prevention methods: voices from young men who have sex
with men. Arch Sex Behav. 2015;44:487–97.
47. Potter N, Lyons-Amos C, Tsiarigli C, Perera G, Hyde T, Brodie C, et al. Health
and wellbeing needs of young adults age 18–25: joint strategic needs
assessment (JSNA) report. London; 2017. https://www.jsna.info/sites/default/
files/YoungAdultsJSNARKBCWCC.pdf. Accessed 17 Jan 2018.
48. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al.
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in
men and transgender women who have sex with men: a cohort study.
Lancet Infect Dis. 2014;14:820–9.
49. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal
intercourse: systematic review, meta-analysis and implications for HIV
prevention. Int J Epidemiol. 2010;39:1048–63.
50. Greene GJ, Swann G, Fought AJ, Carballo-Diéguez A, Hope TJ, Kiser PF, et al.
Preferences for long-acting pre-exposure prophylaxis (PrEP), daily Oral PrEP,
or condoms for HIV prevention among U.S. men who have sex with men.
AIDS Behav. 2017;21(5):1336–49.
51. Dageid W, Govender K, Gordon SF. Masculinity and HIV disclosure among
heterosexual South African men: implications for HIV/AIDS intervention. Cult
Health Sex. 2012;14:925–40.
52. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Pre-exposure
antiretroviral prophylaxis (PrEP) attitudes in high risk Boston area MSM:
limited knowledged and experience, but potential for increased utilization
after education. J Acquir Immune Defic Syndr. 2009;50:77–83.
53. Grov C, Whitfield THF, Rendina HJ, Ventuneac A, Parsons JT. Willingness to
take PrEP and potential for risk compensation among highly sexually active
gay and bisexual men. AIDS Behav. 2015;19:2234–44.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Cheng et al. BMC Public Health          (2019) 19:996 Page 9 of 9
